These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 7728305)

  • 1. Immunologic effects of levamisole in mice and humans: evidence for augmented antibody response without modulation of cellular cytotoxicity.
    Tempero MA; Haga Y; Sivinski C; Birt D; Klassen L; Thiele G
    J Immunother Emphasis Tumor Immunol; 1995 Jan; 17(1):47-57. PubMed ID: 7728305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigating the role of immunomodulation for colon cancer prevention: results of an in vivo dose escalation trial of levamisole with immunologic endpoints.
    Holcombe RF; Milovanovic T; Stewart RM; Brodhag TM
    Cancer Detect Prev; 2001; 25(2):183-91. PubMed ID: 11341354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.
    Haller DG; Catalano PJ; Macdonald JS; O'Rourke MA; Frontiera MS; Jackson DV; Mayer RJ
    J Clin Oncol; 2005 Dec; 23(34):8671-8. PubMed ID: 16314627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity.
    Peng LS; Penichet ML; Morrison SL
    J Immunol; 1999 Jul; 163(1):250-8. PubMed ID: 10384123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levamisole: a double blind immunological study.
    Webster DJ; Whitehead RH; Richardson G; Hughes LE
    Anticancer Res; 1982; 2(1-2):29-32. PubMed ID: 7051958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapeutic effect of Concholepas hemocyanin in the murine bladder cancer model: evidence for conserved antitumor properties among hemocyanins.
    Moltedo B; Faunes F; Haussmann D; De Ioannes P; De Ioannes AE; Puente J; Becker MI
    J Urol; 2006 Dec; 176(6 Pt 1):2690-5. PubMed ID: 17085197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenovirus-interleukin-12-mediated tumor regression in a murine hepatocellular carcinoma model is not dependent on CD1-restricted natural killer T cells.
    Andrews KJ; Ribas A; Butterfield LH; Vollmer CM; Eilber FC; Dissette VB; Nelson SD; Shintaku P; Mekhoubad S; Nakayama T; Taniguchi M; Glaspy JA; McBride WH; Economou JS
    Cancer Res; 2000 Nov; 60(22):6457-64. PubMed ID: 11103813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors.
    Daftarian P; Song GY; Ali S; Faynsod M; Longmate J; Diamond DJ; Ellenhorn JD
    Cancer Res; 2004 Aug; 64(15):5407-14. PubMed ID: 15289349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Bacillus Calmette-Guérin and levamisole on immune responses in young adult and age-immunodepressed mice.
    Bruley-Rosset M; Florentin I; Kiger N; Davigny M; Mathé G
    Cancer Treat Rep; 1978 Nov; 62(11):1641-50. PubMed ID: 728893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Murine dendritic cells pulsed with an anti-idiotype antibody induce antigen-specific protective antitumor immunity.
    Saha A; Chatterjee SK; Foon KA; Primus FJ; Bhattacharya-Chatterjee M
    Cancer Res; 2003 Jun; 63(11):2844-54. PubMed ID: 12782590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomodulation with low dose levamisole in patients with colonic polyps.
    Holcombe RF; McLaren CE; Milovanovic T
    Cancer Detect Prev; 2006; 30(1):94-8. PubMed ID: 16458451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice.
    Berman RM; Suzuki T; Tahara H; Robbins PD; Narula SK; Lotze MT
    J Immunol; 1996 Jul; 157(1):231-8. PubMed ID: 8683120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological alterations induced by adjuvant treatment of postoperative colon carcinoma Duke's B or C with levamisole in combination with 5-FU.
    De Brabander M; Vandebroek J; Wassenaar H; De Crée J; Baisier A; Demoen B; De Ridder R; Jagers E; Roels V; Vogels O
    Anticancer Res; 1995; 15(5B):2271-7. PubMed ID: 8572636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Redirected T-cell cytotoxicity to epithelial cell adhesion molecule-overexpressing adenocarcinomas by a novel recombinant antibody, E3Bi, in vitro and in an animal model.
    Ren-Heidenreich L; Davol PA; Kouttab NM; Elfenbein GJ; Lum LG
    Cancer; 2004 Mar; 100(5):1095-103. PubMed ID: 14983507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines.
    Yamaguchi S; Tatsumi T; Takehara T; Sakamori R; Uemura A; Mizushima T; Ohkawa K; Storkus WJ; Hayashi N
    Cancer; 2007 Oct; 110(7):1469-77. PubMed ID: 17685394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
    Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
    Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
    Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disruption of cell-cell adhesion enhances antibody-dependent cellular cytotoxicity: implications for antibody-based therapeutics of cancer.
    Green SK; Karlsson MC; Ravetch JV; Kerbel RS
    Cancer Res; 2002 Dec; 62(23):6891-900. PubMed ID: 12460904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expansion of natural killer cells in mice transgenic for IgM antibody to ganglioside GD2: demonstration of prolonged survival after challenge with syngeneic tumor cells.
    Kawashima I; Yoshida Y; Taya C; Shitara H; Yonekawa H; Karasuyama H; Tada N; Furukawa K; Tai T
    Int J Oncol; 2003 Aug; 23(2):381-8. PubMed ID: 12851687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumor immunity induced by an anti-idiotype antibody mimicking human Her-2/neu.
    Mohanty K; Saha A; Pal S; Mallick P; Chatterjee SK; Foon KA; Bhattacharya-Chatterjee M
    Breast Cancer Res Treat; 2007 Jul; 104(1):1-11. PubMed ID: 17004107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.